DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN - News) today clarified recent reports that the duration of the bapineuzumab Phase 3 clinical trials may be extended. The protocols for the four Phase 3 trials for bapineuzumab, which are approved by regulatory authorities, are designed for patients to participate for a duration of 18 months. The planned duration of the trials has not changed since the program was announced in December 2007. There are currently no plans to extend the duration of the Phase 3 trials.
